entinostat has been researched along with Psoriasis in 2 studies
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the role of topical Entinostat, a selective inhibitor of histone deacetylases 1 (HDAC1) that has been tested in clinic trials to treat solid tumors and hematological malignancies, in psoriasis therapy." | 4.31 | Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response. ( Jiang, Y; Lai, Y; Lu, S; Wang, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, J | 1 |
| Li, J | 1 |
| Jiang, Y | 1 |
| Lu, S | 1 |
| Lai, Y | 1 |
| Wang, L | 1 |
2 other studies available for entinostat and Psoriasis
| Article | Year |
|---|---|
Construction of a three commitment points for S phase entry cell cycle model and immune-related ceRNA network to explore novel therapeutic options for psoriasis.
Topics: Cell Cycle; Cell Division; Gene Regulatory Networks; Humans; MicroRNAs; Molecular Docking Simulation | 2022 |
Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response.
Topics: Animals; Disease Models, Animal; Eczema; Histone Deacetylase 1; Humans; Imiquimod; Interleukin-17; M | 2023 |